Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 3. Annual reported cases of notifiable diseases, by month*, United States, excluding U.S. Territories and Non-U.S. Residents, 2019
Data from some jurisdictions may be incomplete due to the coronavirus disease 2019 (COVID-19) pandemic. Please see Note #9 at the bottom of the table.
Disease Jan. Feb. Mar. Apr. May June July Aug. Sept. Oct. Nov. Dec. Unknown Total
Anthrax — — — — — — — 1 — — — — — 1
Arboviral diseases
Chikungunya virus disease 7 9 9 9 7 15 25 21 24 20 21 25 — 192
Eastern equine encephalitis virus disease
Neuroinvasive — — — — — 1 1 12 23 — 1 — — 38
Non-neuroinvasive — — — — — — — — — — — — — —
Jamestown Canyon virus disease
Neuroinvasive — — — 1 1 2 6 4 4 5 2 — — 25
Non-neuroinvasive — — — — 1 1 11 1 5 1 — — — 20
La Crosse virus disease
Neuroinvasive — — — — — 2 9 13 15 9 — — — 48
Non-neuroinvasive — — — — — — 1 4 2 — — — — 7
Powassan virus disease
Neuroinvasive — — — 1 8 5 9 4 2 1 5 4 — 39
Non-neuroinvasive — — — — — 1 2 — — — 1 — — 4
St. Louis encephalitis virus disease
Neuroinvasive — — — — — 1 7 3 4 — — — — 15
Non-neuroinvasive — — — — — — — — 1 — — 1 — 2
West Nile virus disease
Neuroinvasive 2 2 2 3 5 18 141 153 238 59 11 2 — 636
Non-neuroinvasive 1 1 — 2 3 9 68 110 119 16 7 2 — 338
Western equine encephalitis virus disease
Neuroinvasive — — — — — — — — — — — — — —
Non-neuroinvasive — — — — — — — — — — — — — —
Babesiosis
Total 14 8 6 11 55 367 766 700 164 78 78 173 — 2,420
Confirmed 8 5 3 5 40 312 682 616 132 64 59 140 — 2,066
Probable 6 3 3 6 15 55 84 84 32 14 19 33 — 354
Botulism
Total 14 12 18 13 18 19 12 15 15 19 20 21 — 196
Foodborne 6 — — — — 2 1 2 4 — 1 4 — 20
Infant 8 11 16 12 17 15 7 9 8 14 16 15 — 148
Other (wound & unspecified) — 1 2 1 1 2 4 4 3 5 3 2 — 28
Brucellosis 6 10 15 8 18 12 16 19 16 14 14 17 — 165
Campylobacteriosis 4,017 4,216 5,063 4,541 5,131 8,512 8,100 8,694 5,712 5,174 5,755 6,594 — 71,509
Candida auris, clinical † 15 10 13 9 6 18 11 23 20 22 17 11 — 175
Carbapenemase-producing carbapenem-resistant Enterobacteriaceae 96 109 138 105 114 155 89 174 110 110 132 151 — 1,483
Chancroid — — 1 — 2 — 2 1 — — 1 1 — 8
Chlamydia trachomatis infection 132,928 140,056 174,703 136,778 140,097 168,411 137,491 187,239 142,728 144,593 168,146 135,533 — 1,808,703
Cholera — 1 2 2 — 1 2 2 3 1 — — — 14
Coccidioidomycosis § 1,270 1,455 1,914 1,360 1,466 1,667 1,461 1,900 1,376 1,352 1,915 1,271 — 18,407
Cryptosporidiosis
Total 653 628 829 797 830 1,137 1,537 2,224 1,506 1,357 1,234 1,243 — 13,975
Confirmed 459 421 540 539 560 819 1,168 1,746 1,143 962 942 886 — 10,185
Probable 194 207 289 258 270 318 369 478 363 395 292 357 — 3,790
Cyclosporiasis 6 12 24 22 74 718 2,099 1,274 239 118 38 79 — 4,703
Dengue virus infections 
Dengue 63 31 23 38 32 52 139 241 277 211 166 141 — 1,414
Dengue-like illness 2 — 1 1 1 4 5 8 5 6 5 5 — 43
Severe dengue — 2 — 1 1 — 3 7 7 4 1 4 — 30
Diphtheria — — — — — — — — 1 — 1 — — 2
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 12 14 22 100 425 1,428 1,586 902 254 254 482 176 — 5,655
Ehrlichia chaffeensis infection 18 18 32 60 210 557 456 342 170 94 60 76 — 2,093
Ehrlichia ewingii infection — — — — 2 12 10 8 6 3 1 1 — 43
Undetermined ehrlichiosis/anaplasmosis 2 2 4 10 17 34 42 30 16 11 7 10 — 185
Giardiasis 911 950 1,179 1,041 987 1,440 1,281 1,937 1,415 1,223 1,293 1,203 — 14,860
Gonorrhea 44,622 44,526 54,271 43,136 44,593 56,440 48,463 65,666 50,967 51,643 60,689 51,376 — 616,392
Haemophilus influenzae, invasive disease
All ages, all serotypes 504 479 672 492 516 660 412 420 365 417 557 649 — 6,143
Age <5 years
Serotype b 1 — 8 — 1 2 1 — 1 — 4 — — 18
Non-b serotype 14 19 31 12 18 12 13 12 17 12 31 22 — 213
Nontypeable 15 20 28 13 11 24 9 18 8 11 12 31 — 200
Unknown serotype 15 20 25 21 24 24 10 14 13 14 29 45 — 254
Hansen's disease 3 6 5 2 14 9 7 4 6 8 6 7 — 77
Hantavirus infection, non-hantavirus pulmonary syndrome ** — — — — 1 — — — 1 — — 1 — 3
Hantavirus pulmonary syndrome — 1 — 2 2 3 — 4 2 1 2 1 — 18
Hemolytic uremic syndrome post-diarrheal 9 4 12 13 31 42 49 49 58 35 49 41 — 392
Hepatitis ††
A, acute 1,434 1,576 1,913 1,646 1,626 2,086 1,648 2,015 1,310 1,159 1,217 1,216 — 18,846
B, acute 226 264 317 259 324 356 279 348 243 267 313 348 — 3,544
B, perinatal infection 3 3 1 1 — 1 2 2 1 1 3 1 — 19
C, acute 393 431 520 490 474 585 420 547 376 390 444 409 — 5,479
Confirmed 285 327 391 368 348 423 314 429 290 303 342 316 — 4,136
Probable 108 104 129 122 126 162 106 118 86 87 102 93 — 1,343
C, perinatal infection 15 15 35 14 15 20 22 20 21 8 16 16 — 217
Human immunodeficiency virus diagnoses 3,241 2,885 3,068 3,048 3,103 3,000 2,977 2,974 2,503 2,579 1,805 540 — 31,723
Influenza-associated pediatric mortality 11 32 28 19 13 9 4 4 6 8 5 21 — 160
Invasive pneumococcal disease §§
All ages 2,064 2,032 2,620 1,914 1,755 1,580 682 784 880 1,176 1,841 2,623 — 19,951
Confirmed 2,029 2,005 2,588 1,890 1,730 1,561 676 771 864 1,161 1,815 2,599 — 19,689
Probable 35 27 32 24 25 19 6 13 16 15 26 24 — 262
Age <5 years 84 96 127 86 112 97 41 47 71 90 116 148 — 1,115
Confirmed 81 94 123 85 111 97 41 44 69 88 112 146 — 1,091
Probable 3 2 4 1 1 — — 3 2 2 4 2 — 24
Legionellosis 498 400 413 348 520 1,151 1,109 1,152 1,145 862 752 540 — 8,890
Leptospirosis 7 3 4 6 6 3 15 19 7 7 8 9 — 94
Listeriosis ¶¶
Total 37 40 58 48 71 121 99 140 101 73 73 67 — 928
Confirmed 36 38 55 44 68 116 92 133 96 66 70 66 — 880
Probable 1 2 3 4 3 5 7 7 5 7 3 1 — 48
Lyme disease
Total 905 854 1,075 1,200 1,970 5,680 7,485 6,642 3,072 2,387 2,141 1,534 — 34,945
Confirmed 560 555 704 742 1,212 3,848 5,285 4,513 2,085 1,591 1,358 1,000 — 23,453
Probable 345 299 371 458 758 1,832 2,200 2,129 987 796 783 534 — 11,492
Malaria 103 93 92 75 134 232 237 308 232 142 136 152 — 1,936
Measles ***
Total 45 98 283 299 191 100 76 37 27 18 7 94 — 1,275
Indigenous 41 90 267 283 181 93 71 36 25 11 7 87 — 1,192
Imported 4 8 16 16 10 7 5 1 2 7 — 7 — 83
Meningococcal disease
All serogroups 31 39 45 26 25 33 18 27 23 21 34 49 — 371
Serogroups ACWY 18 14 14 9 12 12 9 11 6 11 12 11 — 139
Serogroup B 4 3 10 3 1 6 2 3 9 2 10 7 — 60
Other serogroups — 3 1 3 2 4 1 3 4 1 2 — — 24
Unknown serogroup 9 19 20 11 10 11 6 10 4 7 10 31 — 148
Mumps 138 144 421 369 371 412 283 372 257 310 384 319 — 3,780
Novel Influenza A virus infections — — — — 1 — — — — — — — — 1
Pertussis 1,092 1,078 1,298 1,065 1,446 1,784 1,456 1,851 1,338 1,412 2,294 2,503 — 18,617
Plague — — — — — — — — 1 — — — — 1
Poliomyelitis, paralytic — — — — — — — — — — — — — —
Poliovirus infection, nonparalytic — — — — — — — — — — — — — —
Psittacosis — — — — — — — 1 2 — — 1 — 4
Q fever
Total 8 15 16 23 22 30 20 18 17 13 17 13 — 212
Acute 7 11 15 18 20 23 19 17 13 11 14 10 — 178
Chronic 1 4 1 5 2 7 1 1 4 2 3 3 — 34
Rabies
Animal 248 265 396 443 442 390 467 573 520 443 240 218 — 4,645
Human — — — — — — — — — — — — — —
Rubella 1 1 — — — 1 1 2 — — — — — 6
Rubella, congenital syndrome — — — — — — — — — — — 1 — 1
Salmonella Paratyphi infection ††† 10 16 13 14 11 9 7 14 14 15 8 24 — 155
Salmonella Typhi infection §§§ 15 33 40 34 37 41 12 50 46 31 19 51 — 409
Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) ¶¶¶ 2,061 2,307 3,326 3,288 3,980 6,081 6,477 8,799 6,483 5,525 5,632 4,412 — 58,371
Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — — —
Shiga toxin-producing Escherichia coli (STEC) 674 659 1,295 1,225 1,173 2,040 2,029 2,322 1,375 1,164 1,473 1,510 — 16,939
Shigellosis 1,150 1,108 1,345 1,102 1,112 1,688 1,552 2,094 1,524 1,643 2,080 2,176 — 18,574
Smallpox — — — — — — — — — — — — — —
Spotted fever rickettsiosis
Total 78 101 134 231 515 1,059 884 932 523 393 219 138 — 5,207
Confirmed — 2 6 2 12 16 22 28 23 7 3 7 — 128
Probable 78 99 128 229 503 1,043 862 904 500 386 216 131 — 5,079
Streptococcal toxic shock syndrome 45 46 70 49 33 37 24 16 16 22 26 32 — 416
Syphilis
Total, all stages **** 9,398 10,117 12,375 9,915 10,195 12,110 9,814 12,834 10,243 10,464 12,255 10,093 — 129,813
Congenital 138 138 134 135 143 128 184 189 189 167 177 148 — 1,870
Primary and secondary 2,818 2,940 3,656 2,939 3,077 3,629 2,937 4,037 3,094 3,100 3,575 3,190 — 38,992
Tetanus 2 2 1 4 2 3 2 4 2 — 1 3 — 26
Toxic shock syndrome (other than Streptococcal) 2 4 6 4 4 8 4 2 4 1 2 3 — 44
Trichinellosis — — — — — — 2 4 — — 1 — — 7
Tuberculosis 518 519 669 745 780 771 776 800 704 805 676 1,153 — 8,916
Tularemia 4 1 4 14 27 59 40 44 24 21 18 18 — 274
Vancomycin-intermediate Staphylococcus aureus 3 2 8 12 7 7 3 5 9 4 8 8 — 76
Vancomycin-resistant Staphylococcus aureus — — — — 1 — — — 1 — — 1 — 3
Varicella morbidity 590 687 901 740 771 715 519 709 671 610 707 677 — 8,297
Varicella mortality 1 — 1 1 — 1 — — — 2 — — — 6
Vibriosis
Total 111 111 164 143 189 309 354 524 290 198 175 283 — 2,851
Confirmed 34 28 56 67 96 188 240 352 182 117 101 190 — 1,651
Probable 77 83 108 76 93 121 114 172 108 81 74 93 — 1,200
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus — — — — — — — — — — — — — —
Ebola virus — — — — — — — — — — — — — —
Guanarito virus — — — — — — — — — — — — — —
Junin virus — — — — — — — — — — — — — —
Lassa virus — — — — — — — — — — — — — —
Lujo virus — — — — — — — — — — — — — —
Machupo virus — — — — — — — — — — — — — —
Marburg virus — — — — — — — — — — — — — —
Sabia virus — — — — — — — — — — — — — —
Yellow fever — — — — — — — — — — — — — —
Zika virus
Zika virus disease, congenital †††† — — — — — — — — — — — — — —
Zika virus disease, non-congenital 2 — 1 4 — 2 3 5 5 4 1 1 — 28
Zika virus infection, congenital †††† — — — — — — — — — — — — — —
Zika virus infection, non-congenital 11 24 24 19 22 17 19 10 15 6 6 4 — 177
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • * Month is defined using MMWR week (http://wwwn.cdc.gov/nndss/document/MMWR_Week_overview.pdf). MMWR week calendars can be found at http://wwwn.cdc.gov/nndss/script/downloads.aspx.
  • † Candida auris colonization/screening cases are not included in this table. These data are available on the Mycotic Diseases Branch's Tracking Candida auris page (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html)
  • § Reportable in <25 states.
  • ¶ Counts include confirmed and probable dengue cases.
  • ** Includes data for old world hantavirus infections, such as Seoul virus and Puumala virus infections.
  • †† Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • §§ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • ¶¶ Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately
  • *** Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
  • ††† Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • §§§ Beginning in January 2019, cases began to be reported as Salmonella Typhi infection. In previous years, cases were reported as typhoid fever.
  • ¶¶¶ Beginning in January 2019, cases began to be reported as salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • **** Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); and unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations).
  • †††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  2. The list of national notifiable infectious diseases and conditions for 2019 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2019" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2018 by CSTE for national surveillance that were implemented in January 2019. Candida auris, clinical became a new national notifiable condition, and revised case definitions were implemented for the following conditions: diphtheria, acute hepatitis A, listeriosis, yellow fever, Salmonella Paratyphi infection and Salmonella Typhi infection. Salmonella Paratyphi infection and Salmonella Typhi infection replaced Paratyphoid fever and Typhoid fever, respectively, as national notifiable conditions. Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) replaced Salmonellosis (excluding paratyphoid fever and typhoid fever) as a national notifiable condition. In addition, Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) represents a consolidation of CP-CRE species Klebsiella spp, CP-CRE E. coli, and CP-CRE Enterobacter spp. Publication criteria for the finalized 2019 data are available at https://wonder.cdc.gov/nndss/documents/2019_NNDSS _Publication_Criteria_01212021.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2019, estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010, to July 1, 2019, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2019), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released July 9, 2020, are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2019 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on August 6, 2020, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2021. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks, select "Annual Reports" in the "Genre" box to the left).
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal Hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months)
    • Perinatal Hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2019 (National Center for Health Statistics Natality 2019, as compiled from data provided by the Vital Statistics Cooperative Program). The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Congenital syphilis data are published in Syphilis Statistics in the sexually transmitted diseases (STD) surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) and in the historical archives of the STD surveillance report (https://www.cdc.gov/std/stats/archive.htm). The STD surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) updates congenital syphilis cases and rates over time.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. The following 24 jurisdictions may have incomplete data, due to the coronavirus disease 2019 (COVID-19) pandemic: Alaska, California, Connecticut, Delaware, District of Columbia, Florida, Idaho, Indiana, Kansas, Massachusetts, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New York (excluding New York City), New York City, North Dakota, Ohio, Oklahoma, South Carolina, Tennessee, Texas, and West Virginia. In addition, the following 2 U.S. Territories may have incomplete data due to the COVID-19 pandemic: American Samoa and the U.S. Virgin Islands.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.